

Public Abstract

First Name:Stephanie

Middle Name:

Last Name:Lane

Adviser's First Name:Silvia S.

Adviser's Last Name:Jurisson

Co-Adviser's First Name:Charles J.

Co-Adviser's Last Name:Smith

Graduation Term:FS 2009

Department:Chemistry

Degree:PhD

Title:PROSPECTIVE RADIOLABLED BOMBESIN CONJUGATES FOR PROSTATE CANCER IMAGING AND THERAPEUTIC AGENTS

An active area of prostate cancer research is in the synthesis of radiolabeled peptides for in vivo tumor imaging or therapy. This method is possible since specific receptors are expressed in high concentration on certain tumor tissue. One receptor that is expressed in high concentration on prostate cancer tissue is the gastrin-releasing peptide (GRP). The amphibian peptide, bombesin (BBN), has high affinity and specificity to the GRP receptors; therefore, when BBN is radiolabeled with an appropriate radionuclide, non-invasive prostate tumor images and therapy can be obtained. The aim of this research was to produce kinetically inert bifunctional chelate complexes that would effectively contain the radionuclide Rhenium-188 (^{188}Re), Technetium-99m ($^{99\text{m}}\text{Tc}$), Copper-64 (^{64}Cu) or Bismuth-213 (^{213}Bi).